Genetically Encoded Oligomerization for Protein-Based Lighting Devices.

Implementing proteins in optoelectronics represents a fresh idea toward a sustainable new class of materials with bio-functions that can replace environmentally unfriendly and/or toxic components without losing device performance. However, their native activity (fluorescence, catalysis, and so on) is easily lost under device fabrication/operation as non-native environments (organic solvents, organic/inorganic interfaces, and so on) and severe stress (temperature, irradiation, and so on) are involved. Herein, a gift bow genetically-encoded macro-oligomerization strategy is showcased to promote protein-protein solid interaction enabling i) high versatility with arbitrary proteins, ii) straightforward electrostatic driven control of the macro-oligomer size by ionic strength, and iii) stabilities over months in pure organic solvents and stress scenarios, allowing to integrate them into classical water-free polymer-based materials/components for optoelectronics. Indeed, rainbow-/white-emitting protein-based light-emitting diodes are fabricated, attesting a first-class performance compared to those with their respective native proteins: significantly enhanced device stabilities from a few minutes up to 100 h keeping device efficiency at high power driving conditions. Thus, the oligomerization concept is a solid bridge between biological systems and materials/components to meet expectations in bio-optoelectronics, in general, and lighting schemes, in particular.

Origin of acetylcholine antagonism in ELIC, a bacterial pentameric ligand-gated ion channel.

ELIC is a prokaryotic homopentameric ligand-gated ion channel that is homologous to vertebrate nicotinic acetylcholine receptors. Acetylcholine binds to ELIC but fails to activate it, despite bringing about conformational changes indicative of activation. Instead, acetylcholine competitively inhibits agonist-activated ELIC currents. What makes acetylcholine an agonist in an acetylcholine receptor context, and an antagonist in an ELIC context, is not known. Here we use available structures and statistical coupling analysis to identify residues in the ELIC agonist-binding site that contribute to agonism. Substitution of these ELIC residues for their acetylcholine receptor counterparts does not convert acetylcholine into an ELIC agonist, but in some cases reduces the sensitivity of ELIC to acetylcholine antagonism. Acetylcholine antagonism can be abolished by combining two substitutions that together appear to knock out acetylcholine binding. Thus, making the ELIC agonist-binding site more acetylcholine receptor-like, paradoxically reduces the apparent affinity for acetylcholine, demonstrating that residues important for agonist binding in one context can be deleterious in another. These findings reinforce the notion that although agonism originates from local interactions within the agonist-binding site, it is a global property with cryptic contributions from distant residues. Finally, our results highlight an underappreciated mechanism of antagonism, where agonists with appreciable affinity, but negligible efficacy, present as competitive antagonists.